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Abstract
Background: Glomerulopathy with fibronectin deposits is an autosomal dominant disease associated with proteinuria,
hematuria, hypertension and renal function decline. Forty percent of the cases are caused by mutations in FN1, the
gene that encodes fibronectin.
Case presentation: This report describes two cases of Glomerulopathy with fibronectin deposits, involving a 47-year-
old father and a 14-year-old son. The renal biopsies showed glomeruli with endocapillary hypercellularity and large
amounts of mesangial and subendothelial eosinophilic deposits. Immunohistochemistry for fibronectin was markedly
positive. Whole exome sequencing identified a novel FN1 mutation that leads to an amino-acid deletion in both
patients (Ile1988del), a variant that required primary amino-acid sequence analysis for assessment of pathogenicity. Our
primary sequence analyses revealed that Ile1988 is very highly conserved among relative sequences and is positioned
in a C-terminal FN3 domain containing heparin- and fibulin-1-binding sites. This mutation was predicted as deleterious
and molecular mechanics simulations support that it can change the tertiary structure and affect the complex folding
and its molecular functionality.
Conclusion: The current report not only documents the occurrence of two GFND cases in an affected family and
deeply characterizes its anatomopathological features but also identifies a novel pathogenic mutation in FN1, analyzes
its structural and functional implications, and supports its pathogenicity.
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Background
Glomerulopathy with fibronectin deposits (GFND) is a
rare autosomal dominant heterogeneous disorder, charac-
terized by proteinuria, hematuria, hypertension and,
potentially, progression to renal failure [1]. This disease is
caused by pathogenic mutations in the fibronectin-encod-
ing FN1 gene, located in chromosomic region 2q34 - when
the disorder is named GFND2 [2, 3] - or in a locus
mapped to 1q.32 (GFND1) [3]. FN1 is a 2386-amino-acid
(aa) protein with a combination of FN1 type I, II and III
domains (FN1, FN2 and FN3, respectively), involved in cell
adhesion, motility, shape maintenance, opsonization, and
wound healing. GFND manifests more often in the third
or fourth decade of life [3], although this may occur at
other age ranges. Most patients have normal renal func-
tion at diagnosis, usually advancing to end-stage kidney
disease (ESKD) 15–20 years after clinical onset [4].
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In this report, we present two cases of GFND, father
and son, with nephrotic syndrome, hematuria and hyper-
tension associated with a novel FN1 mutation. This vari-
ant consists of an in-frame deletion that most likely leads
to a single aa loss, a variant that required primary amino-
acid sequence analysis to assess its potential pathogenicity.
This evaluation supported its deleterious effect.
Case presentation
A 14-year-old male was admitted with blood pressure of
165/100mmHg, generalized edema, ascites, serum albumin
of 1.4 g/dL, 24-h proteinuria of 5.42 g, hematuria 1+/4+
and serum creatinine of 0.73mg/dL, reflecting an estimated
glomerular filtration rate (eGFR) of 138mL/min/1.73m2
using the Chronic Kidney Disease Epidemiology Collabor-
ation (CKD-EPI) formula. Antineutrophil cytoplasmic, anti-
nuclear and anti-DNA antibodies were negative, as well as
serologies for hepatitis B and C, syphilis and human
immunodeficiency virus (HIV). C3 and C4 levels were
normal.
Renal biopsy showed all glomeruli with mesangial
hypercellularity and large amounts of eosinophilic fucci-
nophilic deposits, while are negative for methenamine sil-
ver and Sirus red in mesangium and subendothelium (Fig.
1A-H). Some capillary loops had basement membrane
double contour. Absence of Congo red staining excluded
amyloidosis, and immunofluorescence for IgA, IgG, IgM,
Kappa, Lambda Transmission-electron microscopy
(TEM), C1q and fibrinogen were negative. Analysis re-
vealed massive electron-dense deposits, granular and glo-
bally present in mesangium, occasionally subendothelial
and rarely subepithelial. There were foci of mesangial
interposition, duplication of basement membrane and foot
process effacement (Fig. 1I-N). Immunohistochemistry
showed marked fibronectin staining in glomerular de-
posits, establishing the diagnosis of GFND (Fig. 1O-P). No
consanguinity was identified and treatment was initiated
with angiotensin I-converting enzyme inhibitor (ACEi).
Renal function remained stable but daily proteinuria per-
sisted between 3.0–5.0 g after three years.
To fully characterize his medical condition, whole exome
sequencing was carried out and detected the novel c.5962_
5964del:p.1988_1988del variant in FN1. This variant was
confirmed by Sanger sequencing. Mutation Taster and
SIFT softwares were used to assess its potential pathogen-
icity, however were not robust enough to yield clear results
given the in-frame deletion pattern. This variant, however,
was not found in the ExAC, 1000G and our local databases,
and the deleted aa is conserved in mammalian and several
non-mammalian species. In addition to the Ile1988 dele-
tion, such programs also brought a less likely possibility of
splice change, with uncertainty about potential protein
sequence changes/truncations. Since the Ile1988 deletion is
present in both situations, and the last possibility includes
additional changes to the protein, pathogenicity analysis
directed to p.1988_1988del was the essential evaluation to
be performed.
Given the limitations of the prediction softwares based
on DNA sequence, we performed primary amino-acid
sequence analysis directed to the Ile1988 deletion in
three levels of complexity to assess the variant likely
deleterious effect. The first one was based on sequence
alignment. Ile1988 deletion is positioned in the 15th fi-
bronectin type III (FN3) domain at the C-terminus. 1273
FN1 relative sequences available in the National Center
for Biotechnology Information (NCBI) Reference Se-
quence database were clustered into 66 representative
sequences and aligned [5]. The resulting alignment
showed a hydrophobic residue at position 1988 in far
most sequences, revealing that the Ile1988 residue is
highly conserved among all FN1 sequences. At the sec-
ond level, the pathogenicity of this deletion was evalu-
ated with PROVEAN [6], yielding a deleterious effect
score of − 7.053. Score values below − 2.5 are consistent
with prediction of a deleterious effect. The third level
and more complex analysis included tertiary FN3 struc-
tural analysis using molecular mechanics. This evalu-
ation included wild-type and mutated models, modeled
with Yet Another Scientific Artificial Reality Application
(YASARA) [7] suite using the human FN3 crystal struc-
ture as template (PDB 3R8Q) and submitted to simula-
tions in explicit solvent. 16,000 trajectories of 100 ps
were calculated with the Yet Another Model Building
and Energy Refinement force field 3 (YAMBER3 force
field) and recorded for each wild-type and mutant
molecule. Comparison analysis revealed that absence of
Ile1988 leads to replacement with Val1987 at the mo-
lecular level. As consequence, the upstream Leu1977-
Val1986 residues had their main chain trace completely
altered, losing their beta-strand conformation present in
the original molecule. In the native FN3 domain, the β-
sheet conformation, composed of four anti-parallel β-
strands, is maintained by a hydrogen bond network and
hydrophobic interactions which are partially disrupted in
the absence of Ile1988. The simulation shows, in fact,
that in the mutated FN3 domain several hydrogen bonds
between the strand main-chain nitrogens and the adja-
cent strand main-chain oxygens are lost or assumed a
non-optimal distance, disrupting a series of hydrophobic
contacts, increasing the flexibility of the whole domain
and jeopardizing the domain structural stability (Fig. 2).
These results are consistent with a floppy mutated sub-
unit, which may affect the folding of the complex and
result in a defective molecule. Altogether, these results
strongly support that the functional activity of the mu-
tated FN1 might be impaired or lost.
The patient’s father was found to have proteinuria of
4.98 g/day, hematuria and hypertension at 47 years of age,
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being placed on the angiotensin receptor blocker (ARB)
losartan. Search for secondary causes of nephrotic syn-
drome was negative. After losing his nephrology follow-up
and two years after his son diagnosis, proteinuria was 5.0
g/day and serum creatinine 1.2mg/dL (eGFR of 72mL/
min/1.73m2). Renal biopsy showed similar findings to his
son’s. Marked fibronectin staining coincided with mesan-
gial and capillary loop deposits, especially in subendothe-
lial space, also establishing the diagnosis. He is currently
on a higher dose of losartan and remains with similar
levels of proteinuria. As expected, the c.5962_5964del:
p.1988_1988del variant was also found in the father but
not detected in the non-affected mother, two brothers and
sister (Fig. 3). No proteinuria or renal dysfunction was de-
tected in the patient’s mother and three siblings.
Discussion and conclusions
GFND was originally described as a familial glomerulopathy
with fibrillar giant deposits [8]. Later demonstration of fi-
bronectin immunoreactivity led to the term famillial glom-
erulonephritis with fibronectin deposits [3]. More recently,
the disease was associated with mutations in FN1,
Fig. 1 Renal histological and ultrastructural findings in the child (a, c, e, g, i, k, m and o) and his father (b, d, f, h, j, l, n, p), affected by
Glomerulopathy with Fibronectin Deposits. a and b - Glomeruli with increased size, lobed, with endocapillary hypercellularity mainly due to
mesangial cells. Eosinophilic, homogeneous coarse deposits in mesangial and subendothelial regions (HE, 20x obj.). c and d - The referred
deposits are negative to Sirius red staining (SR, 20x obj.). e and f - Deposits are also negative to silver impregnation while areas with double
contour of capillary loops can be observed (PAMS, 20x obj.). g and h - The deposits, on the other hand, are positive to Masson’s trichrome stain
(TRI, 20x obj.). i and j - Electron microscopy shows massive electron-dense deposits in mesangium (i) and subendothelial location (j), identified by
arrows (original magnification, × 3000). k and l images show abundant electron-dense deposits in mesangium and capillary loops, predominantly
subendothelial but focally subepithelial in K (identified with a star) (original magnification, × 20,000 in k and × 4400 in l). m and n - In high-power
view, deposits are finely granular (m - original magnification, × 250,000) and in subendothelial location (n - original magnification, × 7000). o and
p - Immunohistochemistry for fibronectin revealing markedly positive giant deposits in mesangium and capillary loops (IH for fibronectin,
20x obj.)
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Fig. 2 Superimposition between the native (white) and mutated (bronze) FN3 domain models. Despite the replacement of the native Ile1988
position with Val1987 in the mutated model, the previous eight residues had their main chain trace completely altered, as well as in other parts
of the molecule. Several contacts were lost so that the mutated model is floppier
Fig. 3 GFND family pedigree
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accounting for about 40% of the cases. As observed in our
patients, typical findings include eosinophilic, homogeneous
and coarse deposits in mesangial and subendothelial re-
gions, negative to Congo red, silver and Sirius red, and posi-
tive for Masson’s trichrome and periodic acid Schiff (PAS)
staining. Glomeruli are increased in size with lobed appear-
ance, have endocapillary hypercellularity mainly due to
mesangial cells and some areas exhibit capillary loop double
contour. Immune complex deposition is classically absent
[1]. IgM and C1q in mesangium has been reported, how-
ever such findings have been assigned to insulation of these
proteins. Electron-dense deposits in mesangial and suben-
dothelial regions are typically seen, most often finely granu-
lar and rarely fibrillary [1]. When present, fibrils are 9–16
nm in diameter and randomly distributed [9].
Diagnostic confirmation requires, in addition to the
TEM findings, strong plasma fibronectin isoform stain-
ing in mesangium and capillary loops. Diagnosis of
GFND may be challenging, however, particularly in the
absence of clinical suspicion, family history and previous
serum tests. Accurate molecular diagnosis, in turn, is
currently available for GFND2 [9].
Fibronectin is an extracellular matrix glycoprotein
with various homologous aa sequences and distinct
motifs with specific domains to bind heparin, collagen,
fibrin and DNA [10]. It includes two 250-kDa units with
type I, II and III domains held together by disulfide brid-
ges. This molecular structure allows it essential roles in
several biological processes, including interaction
between cells and extracellular matrix [11]. Fibronectin
has two isoforms; one cellular, insoluble, and another
circulating, soluble [1]. The cellular form is produced by
glomerular mesangial cells and, in other tissues, mainly
by fibroblasts [10]. The circulating form is synthesized
by hepatocytes and can deposit in glomeruli [3, 12]. Our
primary sequence analyses showed that Ile1988 is very
highly conserved among relative sequences and is posi-
tioned in a key FN3 domain, a 90-residue segment in the
protein C-terminus containing heparin-binding and fibulin-
1-binding domains [13]. Heparin is a mucopolysaccharide
sulfuric acid ester with anticoagulation properties while
fibulin-1 is a glycoprotein found in connective tissues, some
basement membranes and elastic fibers [14]. The c.5962_
5964del:p.1988_1988del mutation was predicted to be dele-
terious and performed simulations suggest that it can
change the molecular structure of the whole domain and
possibly affect the folding of the complex. Such observa-
tions strongly support pathogenicity for this mutation.
In line with our results, the previously described FN1
variants W1925R and L1974R, which affect the same
HepII region, were shown to have less affinity to Heparin
and were associated with impaired capacity of inducing
endothelial cell spreading and cytoskeleton reorganization
[2]. In addition, fibulin, the other protein that interacts
with the region where Ile1988del lies, has been associated
with chronic kidney disease [14].
The mechanism of fibronectin glomerular deposition is
poorly understood [15]. The most likely hypothesis is a
defective clearance of metalloproteinases and abnormal
conformation of plasma fibronectin [3], which dissemi-
nates into tissues and incorporates into the fibrillar matrix
[3, 12]. By modifying fibril formation, mutations in FN1
can also lead to isoform imbalance, allowing plasma fibro-
nectin incorporation into the glomerular nonfibrillar
matrix [2]. Moreover, fibronectin produced in mesangium
could also partially contribute to the deposits [16].
Amyloidosis is the most common glomerulopathy with
fibrillary deposits. Differential diagnoses also include
cryoglobulinemia, fibrillary, immunotactoid and collage-
nofibrotic glomerulonephritis. Distinction is primarily
based on the deposit ultrastructural features, if filament-
ous or with microtubular formation [15], and on the fi-
bril diameter: 8–12 nm in amyloidosis; 18–22 nm in
fibrillary glomerulonephritis, 10–90 nm in immunotac-
toid glomerulonephritis; and 43–65 nm in collagenofi-
brotic glomerulonephritis [4]. Given the paucity of
filamentous structures, the diagnosis of GFND can be
occasionally made by immunoelectron microscopy [15].
There is no specific treatment for GFND. However, if
diagnosed early, improvement in clinical status may be
achieved at least temporarily with drugs, especially
ACEis or ARBs [1]. Such agents were used in our cases,
being associated with relatively preserved renal function
but maintained nephrotic-range proteinuria. Although
the prognosis of GFND is unknown [15], ESKD cases
can be submitted to any renal replacement therapy, in-
cluding transplantation [1]. Recurrence is possible, how-
ever, given the persistence of abnormal circulating
fibronectin [4], but additional studies are needed to de-
termine this risk.
The current report not only documents the occurrence
of two GFND cases in an affected family and deeply
characterizes its anatomopathological features but also
identifies a novel pathogenic mutation in FN1, analyzes
its structural and functional implications, and supports
its pathogenicity.
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